During the past decade, NeuroConcept AG C/O mind mvz GmbH conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "NeuroConcept AG C/O mind mvz GmbH" are "Multiple Sclerosis, Relapsing-Remitting" (1 trials) and "Progressive Multiple Sclerosis (PMS)" (1 trials). Many other conditions were trialed in "NeuroConcept AG C/O mind mvz GmbH" in a lesser frequency.

Most popular intervention types in "NeuroConcept AG C/O mind mvz GmbH" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "NeuroConcept AG C/O mind mvz GmbH" are 2 trials for "All" genders.

Currently, there are NaN active trials in "NeuroConcept AG C/O mind mvz GmbH". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in NeuroConcept AG C/O mind mvz GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in NeuroConcept AG C/O mind mvz GmbH, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".